BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26913801)

  • 21. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor agonists for treating prolactinomas.
    Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical treatment of prolactinomas.
    Molitch ME
    Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prolactinoma and pregnancy].
    Trifonov I
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Liu C; Tyrrell JB
    Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of treatments for prolactinomas.
    Auriemma RS; Grasso LF; Pivonello R; Colao A
    Expert Opin Drug Saf; 2016; 15(4):503-12. PubMed ID: 26855238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactinoma and pregnancy.
    Randeva HS; Davis M; Prelevic GM
    BJOG; 2000 Sep; 107(9):1064-8. PubMed ID: 11002946
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of prolactinomas in Brazil: an electronic survey.
    Vilar L; Naves LA; Casulari LA; Azevedo MF; Albuquerque JL; Serfaty FM; Pinho Barbosa FR; de Oliveira AR; Montenegro RM; Montenegro RM; Ramos AJ; Dos Santos Faria M; Musolino NR; Gadelha MR; Boguszewski CL; Bronstein MD
    Pituitary; 2010 Sep; 13(3):199-206. PubMed ID: 20107911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
    Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolactinomas and pregnancy.
    Molitch ME
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
    [No Abstract]   [Full Text] [Related]  

  • 35. Macroprolactinoma: a diagnostic and therapeutic update.
    Iglesias P; Díez JJ
    QJM; 2013 Jun; 106(6):495-504. PubMed ID: 23329574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
    Pereira AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine Agonists: From the 1970s to Today.
    Auriemma RS; Pirchio R; De Alcubierre D; Pivonello R; Colao A
    Neuroendocrinology; 2019; 109(1):34-41. PubMed ID: 30852578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.